Independent Researcher in AI-Driven Industrial Competitiveness#
Welcome to my research platform exploring the intersection of artificial intelligence, industrial strategy, and emerging technologies.
Research Focus#
My work centers on understanding how AI is reshaping competitive dynamics across semiconductors, advanced materials, and AI-enabled biological systems research. Through quantitative analysis and industry insights, I examine the strategic implications of AI-driven transformation for businesses and industries.
Core Research Areas#
AI & Semiconductor Valuation
Developing frameworks for analyzing competitive positioning and market dynamics of AI chip companies in an era of rapid technological change.
Industrial Strategy
Examining how artificial intelligence is transforming traditional manufacturing sectors and creating new paradigms for competitive advantage.
Biotech & AI Integration
Exploring AI-enabled biological systems modeling and life-science research applications in industrial contexts (non-clinical, non-medical).
Materials Innovation
Analyzing innovation pathways and strategic positioning in specialty chemicals and advanced materials industries.
Selected Work#
-
Multi-Target Gene Therapy for Osteoarthritis: A Computational Framework – Research Square (2026) | DOI: 10.21203/rs.3.rs-8774255/v1
-
Patent Quality vs Quantity in Intangible Economy – Zenodo (2026) | DOI: 10.5281/zenodo.18437953
-
Policy-Conditioned Dynamic Capabilities and AI-Driven Valuation – SSRN (2025) | Working Paper No. 5843722
-
AI Semiconductor Valuation Dataset (95 global firms) – Quantitative analysis using GEE regression and Random Forest models
About Me#
Sinclair Huang 是一位專注於人工智慧（AI）、實體基礎設施與資本市場交叉領域的獨立研究員與企業顧問。他擁有 HEC Liège（列日大學管理學院）的企業管理高階博士學位 (EDBA)，在台灣電子、生技與化工產業擁有逾 30 年跨產業高階管理經驗，目前擔任大陸炭素股份有限公司董事長特別顧問。
其研究重點涵蓋 AI 驅動的價值重分配、半導體策略，以及實體基礎設施指標如何重塑現代產業競爭優勢，研究成果發表於 SSRN、Zenodo、Research Square 及 Medium。
Sinclair Huang is an independent researcher and executive advisor specializing in the intersection of Artificial Intelligence, physical infrastructure, and capital markets. He holds an Executive Doctorate in Business Administration (EDBA) from HEC Liège, with over 30 years of cross-industry leadership experience across Taiwan’s electronics, biotechnology, and chemical sectors.
Currently serving as Special Advisor to the Chairman at Continental Carbon Co., Ltd., his research focuses on AI-driven value redistribution, semiconductor strategy, and infrastructure-led indicators reshaping industrial competitiveness. His work is published through SSRN, Zenodo, Research Square, and Medium.
View Publications → | ORCID: 0009-0007-8173-5672
Why is everyone suddenly talking about CoWoS, HBM, and ABF whenever AI, NVIDIA, or AI servers come up? Many people know they are important, but still get stuck the first time they run into these terms.
This essay is a plain‑language walkthrough of what they actually are, why they are always mentioned together, and how they map onto Taiwan’s role in the global AI supply chain.
When Google, Amazon, and Tesla are all designing their own chips, is Taiwan’s manufacturing ecosystem still structurally important — or just enjoying a temporary window?
...
Every layer that looks solved hides another constraint beneath it.
§1 The Illusion of Infinite Compute The headlines say NVIDIA is winning. The hyperscalers are spending. The models are getting bigger.
But the real question is not where demand is going. It is where compute, physically, can still be built fast enough to meet it.
The harder answer requires tracing the full physical stack — from silicon wafer, through memory stack, through packaging interposer, through substrate material — and asking at each layer: can this actually scale at the speed the demand curve requires?
...
AI in drug discovery is often framed as a speed story. Faster screening, faster structure prediction, faster candidate generation.
But speed is only the surface.
What AI really changes is the way search space is organized. In traditional drug discovery, much of the challenge lies not only in testing compounds, but in deciding where to look. AI expands the ability to navigate vast biological and chemical spaces, but it does not eliminate the underlying uncertainty of biology itself.
...
For years, digital strategy was built around owning traffic and bringing users back to a company website.
That logic may be weakening.
As AI systems become better at summarizing, filtering, comparing, and presenting options directly to users, the key source of value may shift from website ownership to interface control. In other words, the winner may not always be the company with the best homepage, but the company, platform, or system that controls how customer intent is interpreted and how choices are presented.
...
In every wave of commerce, people tend to focus on tools first.
They talk about better platforms, smoother interfaces, lower friction, faster conversion, and now AI-driven recommendation systems. But the first principle of commerce has not changed.
Trust comes before efficiency.
Before a customer asks whether a platform is convenient, they ask whether the product is real, whether the seller is credible, and whether the transaction can be completed safely. This was true in early e-commerce, and it remains true in the AI era.
...
Quick thoughts on how AlphaFold 3 is transforming molecular medicine